A Phase 2 interventional study of zilucoplan and Placebo in Immune Mediated Necrotizing Myopathy, sponsored by Ra Pharmaceuticals. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.
Among the 99 studies in Muscular Diseases with a site in United States, this one is the 37th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2019, is one of 10 in phase 2, and was the 58th registered.
232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.
Browse Muscular Diseases studies →19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
University of Alabama at Birmingham · Sites in United States
Ages 16+
AstraZeneca · Sites in United States, Canada, China and 7 more countries
Ages 18–70
Kite, A Gilead Company · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 18 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 38 across 134 interventional studies indexed under Muscular Diseases.
Median enrollment 38 across the 66 interventional studies, 70 across the 30 observational. Of the 63 that completed or were terminated, 31 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 99 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ra Pharmaceuticals, one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
UCB S.A. has 2 studies filed under Muscular Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Muscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06599697University of Alabama at BirminghamThe MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | 2026-12-30 |
| NCT06374719Clinic for Special ChildrenWiTNNess - TNNT1 Myopathy Natural History Study | 2027-01-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT02842424University of NebraskaRamipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 99 studies in Muscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily subcutaneous (SC) injection
Drug: zilucoplan
Daily subcutaneous (SC) injection
Other: Placebo
Daily subcutaneous (SC) inection
Daily subcutaneous (SC) inection
Percentage Change From Baseline to Week 8 in Serum Creatine Kinase (CK) Levels
All laboratory samples were obtained prior to administration of study drug at applicable visits. CK levels were measured by a central laboratory.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)
A TEAE was defined as: * An adverse event (AE) that occurred after study treatment start that was not present at the time of treatment start. * An AE that increased in severity after treatment start if the event was present at the time of treatment start.
Time frame: Baseline (Day 1) to end of Main Portion (Week 8)
Number of Participants Who Achieve at Least Minimal Response Based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Response Criteria Scale
The ACR/EULAR scale utilized a conjoint analysis-based continuous model using absolute percent change from Baseline in core set measures (physician, patient, and Myositis Disease Activity Assessment Tool (MDAAT); muscle strength; Health Assessment Questionnaire (HAQ); and muscle enzyme levels). A total improvement score (range 0-100) was determined by summing scores for each core set measure and comparing improvement in each respective core set measure. The threshold for minimal improvement was ≥20 in the total improvement score with higher scores indicating a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in Triple Timed Up and Go Test (3TUG) Time
The 3TUG test involved the ambulatory participant getting up from a seated position in a chair, walking at their normal pace for 3 meters, turning around, walking back to the chair, and sitting down. This sequence was repeated 3 times without rest, and the 3TUG test time is the average of the 3 lap times. A negative change from baseline indicated a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in Proximal Manual Muscle Testing (MMT) Score
The proximal MMT assessed muscle strength using manual muscle testing in 7 muscle groups (left and right sides assessed separately). The total MMT score for this study, inclusive of both sides, could range from 0-140, where 0 means no strength in any muscles and 140 means full strength in all the muscles examined. A negative change from Baseline indicated a worse outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in Physician Global Activity Visual Analogue Scale (VAS) Score
The Physician Global Activity VAS Score measured the treating physician's global evaluation of the participant's overall disease activity using a 10 cm VAS labelled with "no activity" at the left end and "maximum activity" at the right end. The Physician Global Activity VAS Score ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in Patient Global Activity VAS Score
The Patient Global Activity VAS Score measured the treating participant's global evaluation of their overall disease activity using a 10 cm VAS labelled with "no activity" at the left end and "maximum activity" at the right end. The Patient Global Activity VAS score ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in HAQ Score
The HAQ had 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities with 2 to 3 questions for each section. Scoring within each section ranged from 0 (without any difficulty) to 3 (unable to do). The total HAQ score was then calculated by summing the scores and dividing by the number of categories answered. The total HAQ score for this study could range from 0-3, where 0 means no functional impairment and 3 means complete functional impairment. A negative change from Baseline indicated a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in MDAAT Extramuscular Disease Activity VAS Score
The MDAAT extramuscular disease activity VAS score measured the degree of disease activity of extramuscular organ systems and muscle. The scoring was performed by the physician and ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
Change From Baseline to Week 8 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score
The FACIT-Fatigue Scale is a 13-item tool which measured an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 4-point Likert scale. The total FACIT-Fatigue Scale score for this study could range from 0-52, where 0 means the participants were very much fatigued during their usual daily activities and 52 means the participants were not at all fatigued during their usual daily activities. A negative change from Baseline indicated a worse outcome.
Time frame: Baseline (Day 1) and end of Main Portion (Week 8)
This study was performed in 4 countries (France, the Netherlands, the United Kingdom, and the United States of America) between 07 November 2019 and 14 June 2021.
| Milestone | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Started | 15 | 12 |
| Completed main portion | 15 | 12 |
| Started main portion safety follow-up | 2 | 0 |
| Completed main portion safety follow-up | 0 | 0 |
| Started extension portion | 13 | 12 |
| Completed | 0 | 0 |
| Not completed | 15 | 12 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Study terminated by sponsor | 10 | 9 |
| Withdrew: Physician decision | 3 | 1 |
All laboratory samples were obtained prior to administration of study drug at applicable visits. CK levels were measured by a central laboratory.
| percentage change | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Percentage Change From Baseline to Week 8 in Serum Creatine Kinase (CK) Levels | -20.72 ± 31.22 | -9.86 ± 26.06 |
A TEAE was defined as: * An adverse event (AE) that occurred after study treatment start that was not present at the time of treatment start. * An AE that increased in severity after treatment start if the event was present at the time of treatment start.
| Participants | Main Portion: Placebo | Main Portion: Zilucoplan 0.3 mg/kg |
|---|---|---|
| Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) | 13 | 9 |
The ACR/EULAR scale utilized a conjoint analysis-based continuous model using absolute percent change from Baseline in core set measures (physician, patient, and Myositis Disease Activity Assessment Tool (MDAAT); muscle strength; Health Assessment Questionnaire (HAQ); and muscle enzyme levels). A total improvement score (range 0-100) was determined by summing scores for each core set measure and comparing improvement in each respective core set measure. The threshold for minimal improvement was ≥20 in the total improvement score with higher scores indicating a better outcome.
| Participants | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Number of Participants Who Achieve at Least Minimal Response Based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Response Criteria Scale | 7 | 6 |
The 3TUG test involved the ambulatory participant getting up from a seated position in a chair, walking at their normal pace for 3 meters, turning around, walking back to the chair, and sitting down. This sequence was repeated 3 times without rest, and the 3TUG test time is the average of the 3 lap times. A negative change from baseline indicated a better outcome.
| seconds | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in Triple Timed Up and Go Test (3TUG) Time | -0.712 ± 0.789 | -1.401 ± 0.788 |
The proximal MMT assessed muscle strength using manual muscle testing in 7 muscle groups (left and right sides assessed separately). The total MMT score for this study, inclusive of both sides, could range from 0-140, where 0 means no strength in any muscles and 140 means full strength in all the muscles examined. A negative change from Baseline indicated a worse outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in Proximal Manual Muscle Testing (MMT) Score | -0.18 ± 3.44 | 3.71 ± 3.81 |
The Physician Global Activity VAS Score measured the treating physician's global evaluation of the participant's overall disease activity using a 10 cm VAS labelled with "no activity" at the left end and "maximum activity" at the right end. The Physician Global Activity VAS Score ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in Physician Global Activity Visual Analogue Scale (VAS) Score | -0.626 ± 0.557 | -0.830 ± 0.671 |
The Patient Global Activity VAS Score measured the treating participant's global evaluation of their overall disease activity using a 10 cm VAS labelled with "no activity" at the left end and "maximum activity" at the right end. The Patient Global Activity VAS score ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in Patient Global Activity VAS Score | -0.685 ± 0.707 | -1.966 ± 0.854 |
The HAQ had 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities with 2 to 3 questions for each section. Scoring within each section ranged from 0 (without any difficulty) to 3 (unable to do). The total HAQ score was then calculated by summing the scores and dividing by the number of categories answered. The total HAQ score for this study could range from 0-3, where 0 means no functional impairment and 3 means complete functional impairment. A negative change from Baseline indicated a better outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in HAQ Score | 0.022 ± 0.151 | -0.125 ± 0.183 |
The MDAAT extramuscular disease activity VAS score measured the degree of disease activity of extramuscular organ systems and muscle. The scoring was performed by the physician and ranged from 0 (absent extramuscular disease activity) to 10 (maximum extramuscular disease activity). A negative change from Baseline indicated a better outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in MDAAT Extramuscular Disease Activity VAS Score | -0.144 ± 0.336 | -0.287 ± 0.398 |
The FACIT-Fatigue Scale is a 13-item tool which measured an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue was measured on a 4-point Likert scale. The total FACIT-Fatigue Scale score for this study could range from 0-52, where 0 means the participants were very much fatigued during their usual daily activities and 52 means the participants were not at all fatigued during their usual daily activities. A negative change from Baseline indicated a worse outcome.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 8 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score | 3.45 ± 3.41 | 8.98 ± 4.08 |
Collected over Baseline (Day 1) to End of Safety Follow-up (Week 83). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Portion: Placebo | 0/15 (0%) | 3/15 (20%) | 13/15 (86.7%) |
| Main Portion: Zilucoplan 0.3 mg/kg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Extension Portion: Zilucoplan 0.3 mg/kg | 1/25 (4%) | 8/25 (32%) | 15/25 (60%) |
| Event | Main Portion: Placebo | Main Portion: Zilucoplan 0.3 mg/kg | Extension Portion: Zilucoplan 0.3 mg/kg |
|---|---|---|---|
| COVID-19Infections and infestations | 0/15 | 0/12 | 3/25 |
| Ventricular tachycardiaCardiac disorders | 1/15 | 0/12 | 0/25 |
| Rhinovirus infectionInfections and infestations | 1/15 | 0/12 | 0/25 |
| Urinary tract infectionInfections and infestations | 1/15 | 0/12 | 0/25 |
| Liver function test increasedInvestigations | 1/15 | 0/12 | 0/25 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/15 | 0/12 | 0/25 |
| Rectal haemorrhageGastrointestinal disorders | 0/15 | 0/12 | 1/25 |
| AstheniaGeneral disorders | 0/15 | 0/12 | 1/25 |
| Sinusitis bacterialInfections and infestations | 0/15 | 0/12 | 1/25 |
| Staphylococcal sepsisInfections and infestations | 0/15 | 0/12 | 1/25 |
| Event | Main Portion: Placebo | Main Portion: Zilucoplan 0.3 mg/kg | Extension Portion: Zilucoplan 0.3 mg/kg |
|---|---|---|---|
| HeadacheNervous system disorders | 4/15 | 4/12 | 2/25 |
| NauseaGastrointestinal disorders | 3/15 | 3/12 | 0/25 |
| VertigoEar and labyrinth disorders | 2/15 | 0/12 | 1/25 |
| FallInjury, poisoning and procedural complications | 0/15 | 0/12 | 3/25 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 1/12 | 2/25 |
| PalpitationsCardiac disorders | 0/15 | 1/12 | 0/25 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/15 | 1/12 | 0/25 |
| Injection site painGeneral disorders | 1/15 | 1/12 | 1/25 |
| Injection site pruritusGeneral disorders | 0/15 | 1/12 | 1/25 |
| Injection site erythemaGeneral disorders | 0/15 | 1/12 | 0/25 |
Intent-to-Treat (ITT) Population included all randomized participants.
| Age, Continuous(years) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Mean | 52.8 ± 13.6 | 56.9 ± 9.0 | 54.6 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 8 | 6 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 9 |
| Not Hispanic or Latino | 8 | 5 | 13 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| American Indian/Alaska native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| White | 10 | 7 | 17 |
| Other/Mixed | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Missing | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Nov 2019 to primary completion in Mar 2021, 15 months.
Results were first posted in May 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan